Clinical Impact of 18F-FDG PET in Thyroid Carcinoma Patients with Elevated Thyroglobulin Levels and Negative 131I Scanning Results After Therapy
Badia O. Helal,
Pascal Merlet,
Marie-Elisabeth Toubert,
Brigitte Franc,
Claire Schvartz,
Halène Gauthier-Koelesnikov,
Alain Prigent and
André Syrota
Service de Médecine Nucléaire, Hôpital Antoine Béclère, AP-HP, Clamart; Département de la Recherche Médicale, Service Hospitalier Frédéric Joliot, CEA, Orsay; Service de Médecine Nucléaire, Hôpital Saint-Louis, Paris; Service dAnatomie Pathologie Hôpital Ambroise Paré, Boulogne; Service de Médecine Nucléaire, Institut Jean-Godinot, Reims; and Service de Médecine Nucléaire, Hôpital Henri-Mondor, Créteil, France

View larger version (38K):
[in a new window]
|
FIGURE 1. A 64-y-old woman with lung metastases from Hürthle-cell carcinoma. FDG PET confirmed lung metastases and revealed mediastinal lymph node metastasis. (A) Coronal slice shows both right lung and mediastinal lymph node metastases. (B) Axial slice confirms multiple left lung metastases (patient 5, group 1).
|
|

View larger version (48K):
[in a new window]
|
FIGURE 2. A 28-y-old man with papillary thyroid cancer who had previously required 2 cervical lymph node dissections. Neck sonography was negative, but FDG visualized on the coronal (A) and sagittal (B) slices 2 right cervical lymph nodes that were confirmed pathologically to be metastases (patient 27, group 2).
|
|
Copyright © 2001 by the Society of Nuclear Medicine.